@article{00fdab4811574fe6ac151a5990edd629,
title = "Regression of Fibrosis Following Hepatitis C Eradication",
author = "Friedman, {Scott L.}",
note = "Funding Information: Dr Friedman has performed consulting activities for 89bio, Agomab, Axcella Health, Blade Therapeutics, Can-Fite Bio-Pharma, Escient Pharmaceuticals, Fate Therapeutics, Fibro-cor, Forbion, Galmed, Gordian Biotechnology, Glycotest, Glympse Bio, HepGene, Insitro, Korro Bio, Merck, Metrea (Foresite), Morphic Therapeutic, NorthSea Therapeutics, Novartis, Ochre Bio, Pfizer, ProSciento Research, Resolution Therapeutics, Satellite Bio, Scholar Rock, Surrozen, and Yaqrit. He has had stock options (all <1% of company value) for Blade Therapeutics, Escient Pharmaceuticals, Galectin, Galmed, Genfit, Glympse Bio, HepGene, LifeMax, Meta-crine, Morphic Therapeutic, Nimbus, NorthSea Therapeutics, Satellite Bio, Scholar Rock, and Surrozen. He has owned stock in Intercept, Madrigal, and Group K. He has performed research activities for Morphic Therapeutic (contract studies), Novo Nordisk (contract studies), Abalone Bio (SBIR grant), Galmed (contract studies), Cincera Therapeutics (contract studies), and Pionyr.",
year = "2022",
month = oct,
language = "English",
volume = "18",
pages = "599--601",
journal = "Gastroenterology and Hepatology",
issn = "1554-7914",
publisher = "Gastro-Hep Communications, Inc.",
number = "10",
}